Combaret V et al. (1997) Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression. Br J Cancer 75:1151-1155
Combaret V et al. (2002) Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res 62:3646-3648
Cooper R et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features - a report from the Children's Cancer Group. Med Pediatr Oncol 36:623-629 Cotterill SJ et al. (2000) Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neu-roblastoma Study Group "Survey" 1982-1992. Eur J Cancer 36:901-908
Cushing HSW (1927) The transformation of a malignant par-avertebral sympathicoblastoma into a benign ganglioneu-roma. Am J Pathol 3:203-216 De Bernardi B et al. (2001) Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 19:183-190 De la Monte SM et al. (1983) Nonrandom distribution of metastases in neuroblastic tumors. Cancer 52:915-925 Dluhy RG (2002) Pheochromocytoma: death of an axiom.
N Engl J Med 346:1486-1488 DuBois SG et al. (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181-189 Dulguerov P et al. (2001) Esthesioneuroblastoma: a meta-
analysis and review. Lancet Oncol 2:683-690 El Shafie M et al. (1983) Intractable diarrhea in children with VIP-
secreting ganglioneuroblastomas. J Pediatr Surg 18:34-36 Evans AE et al. (1971) A proposed staging for children with neu-
roblastoma. Cancer 27:374-378 Evans AE et al. (1990) A comparison of four staging systems for localized and regional neuroblastoma: a report from the Childrens Cancer Study Group. J Clin Oncol 8:678-588 Garaventa A et al. (2002) Localized unresectable neuroblas-toma: results of treatment based on clinical prognostic fac-tors.Ann Oncol 13:956-964 Geoerger B et al. (2001) Metabolic activity and clinical features of primary ganglioneuromas. Cancer 91:1905-1913 Greenberg RE (1957) New diagnostic test for neural tumors in infancy: increased urinary excretion of 3-methoxy-4-hy-droxymandelic acid and norepinephrin in a ganglioneuro-ma with chronic diarrhea. Pediatrics 24:683-684 Guo C et al. (1999) Allelic deletion at 11q23 is common in MYCN
single copy neuroblastomas. Oncogene 18:4948-4957 Hallstensson K et al. (1997) Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma. Eur J Cancer 33:1966-1970 Hann HW, Bombardieri E (2000) Serum markers and prognosis in neuroblastoma: Ferritin, LDH, NSE. In: Brodeur G, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma. Elsevier, Amsterdam, pp 371-381 Hann HW et al. (1981) Biologic differences between neuroblastoma stages IV-S and IV. Measurement of serum ferritin and E-rosette inhibition in 30 children. N Engl J Med
Hann HW et al. (1985) Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Chil-drens Cancer Study Group experience. Cancer Res 45: 2843-2848
Hero B et al. (2001) Evaluation of catecholamine metabolites, MIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol 36:220-223 Hero B et al. (2002) Neuroblastoma preoperatively treated as nephroblastoma: Does inadequate therapy worsen the prognosis? Klin Padiatr 214:157-161 Hero B et al. (2000) Regression in stage 2 and 3 infant neuro-blastoma: results of the prospective German neuroblas-toma trial. Adv Neuroblastoma Res. Abstract, 15-18 May, Philadelphia, P20 Hsiao RJ et al. (1990) Chromogranin A in children with neu-roblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest 85:1555-1559 Hutchinson R (1907) On suprarenal sarcoma in children with metastases in the skull. Q J Med 1:33-38 Ikeda H et al. (2002) Experience with international neuroblas-toma staging system and pathology classification. Br J Cancer 86:1110-1116
Jaffe R et al. (1984) The neuroectodermal tumor of bone. Am J
Surg Pathol 8:885-898 Kaneko M et al. (2002) Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24:613-621 Katzenstein HM et al. (2001) Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol 19:1047-1055 Khan J et al. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7:673-679 Kogner et al. (1993) Neuropeptide Y in neuroblastoma: increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Med Pediatr Oncol 21:317-322 Kramer K et al. (1997) Monoclonal antibody to human Trk-A: diagnostic and therapeutic potential in neuroblastoma. Eur J Cancer 33:2090-2091 Krams M et al. (2002) Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer 94:854-861 Kushner BH et al. (1996) International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. J Clin Oncol 14:2174-2180 Ladenstein R et al. (1998) Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953-965 Ladenstein R et al. (2001) Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med Pediatr Oncol 36:83-92
Lastowska M et al. (2001) Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19:3080-3090 Lau L (2002) Neuroblastoma: a single institution's experience with 128 children and an evaluation of clinical and biological prognostic factors. Pediatr Hematol Oncol 19:79-89 Laug WE et al. (1978) Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 62:77-83
Lilling G et al. (1994) Inhibition of human neuroblastoma growth by a specific VIP antagonist. J Mol Neurosci 5:231239
Look AT et al. (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9:581-591 Marchand F (1891) Beiträge zur Kenntnis der normalen und pathologischen Anatomie der Glandula carotica und der Nebennieren. Virchows Arch 5:578 Maris JM et al. (2001) Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol 36:32-36 Mason GA, Hart-Mercer J, Miller E (1957) Adrenalin-secreting neuroblastoma in an infant. Lancet 273:322-325 Mathew P et al. (2001) Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia 3:105-109 Mora J et al. (2001) Neuroblastic and schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res 61:6892-6898 Ng YY, Kingston JE (1993) The role of radiology in the staging of neuroblastoma. Clin Radiol 47:226-235 Nickerson HJ et al. (2000) Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 18:477-486
Norris MD et al. (1996) Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231-238 Pearson ADJ, Philipp T (2000) Prognosis of low-risk and high-risk neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma. Elsevier, Amsterdam, pp
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.